Global chemotherapy-induced neutropenia therapeutics market forecast
Technavio’s market research analysts have identified this growing preference for chemotherapy among cancer patients will be one of the primary factors driving the growth of the chemotherapy-induced neutropenia therapeutics market. According to our newest report on chemotherapy-induced neutropenia market, this industry will witness a steady growth during the next few years and register a CAGR of almost 6% by 2022.
With the growing instances of cancer, several organizations are focusing on creating awareness about the various options available for cancer. This as per pur industry experts, will be a key trend that will gain traction in the chemotherapy-induced neutropenia therapeutics market during the forecast period.
Want a bigger picture? Try a FREE sample of this report now!
See the complete table of contents and list of exhibits, as well as selected illustrations and example pages from this report
Chemotherapy Market Report: Companies covered
The market is characterized by the presence of a large number of companies and is quite competitive with all the companies constantly focusing on improving their market positions. By providing an analysis of the companies in this market and offering information on the strategies they follow, this report will help clients sustain the market’s competitive environment. Additionally, the report also offers information about various R&D activities the players are focusing on to introduce innovative solutions, that will help them improve their market positions.
This research report provides an analysis of various companies in the neutropenia chemotherapy market including –
- Amgen
- Intas Pharmaceuticals
- Novartis
- Partner Therapeutics
- Teva Pharmaceuticals Industries
Segmentation by geography and analysis of the chemotherapy-induced neutropenia therapeutics market
According to the Centers for Disease Control and Prevention (CDC), almost 2 million new cases of cancer were registered in the US during 2017. This growing patient population will boost the demand for CIN therapeutics, positively influencing the growth of the neutropenia chemotherapy market in the Americas during the next few years.
Get more value with Technavio’s INSIGHTS subscription platform! Gain easy access to all of Technavio’s reports, along with on-demand services. Try the demo
Key questions answered in the report include
- What will the market size and the growth rate be in 2022?
- What are the key factors driving the global chemotherapy-induced neutropenia therapeutics market?
- What are the key market trends impacting the growth of the global chemotherapy-induced neutropenia therapeutics market?
- What are the challenges to market growth?
- Who are the key vendors in the global chemotherapy-induced neutropenia therapeutics market?
- What are the market opportunities and threats faced by the vendors in the global chemotherapy-induced neutropenia therapeutics market?
- What are the trending factors influencing the market shares of the Americas, APAC, and EMEA?
- What are the key outcomes of the five forces analysis of the global chemotherapy-induced neutropenia therapeutics market?
Technavio also offers customization on reports based on specific client requirement.
PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
PART 03: RESEARCH METHODOLOGY
PART 04: MARKET LANDSCAPE
- Market ecosystem
- Market characteristics
- Market segmentation analysis
PART 05: MARKET SIZING
- Market definition
- Market sizing 2017
- Market size and forecast 2017-2022
PART 06: FIVE FORCES ANALYSIS
- Bargaining power of buyers
- Bargaining power of suppliers
- Threat of new entrants
- Threat of substitutes
- Threat of rivalry
- Market condition
PART 07: MARKET SEGMENTATION BY PROCEDURE
- Segmentation by procedure
- Comparison by procedure
- G-CSF therapy – Market size and forecast 2017-2022
- Granulocyte transfusion – Market size and forecast 2017-2022
- Antibiotic therapy – Market size and forecast 2017-2022
- Splenectomy – Market size and forecast 2017-2022
- Market opportunity by procedure
PART 08: CUSTOMER LANDSCAPE
PART 09: REGIONAL LANDSCAPE
- Geographical segmentation
- Regional comparison
- Americas – Market size and forecast 2017-2022
- EMEA – Market size and forecast 2017-2022
- APAC – Market size and forecast 2017-2022
- Key leading countries
- Market opportunity
PART 10: DECISION FRAMEWORK
PART 11: DRIVERS AND CHALLENGES
- Market drivers
- Market challenges
PART 12: MARKET TRENDS
- Increase in global awareness about cancer treatments
- Technological advancements
- Strategic alliances
PART 13: VENDOR LANDSCAPE
- Overview
- Landscape disruption
PART 14: VENDOR ANALYSIS
- Vendors covered
- Vendor classification
- Market positioning of vendors
- Amgen
- Intas Pharmaceuticals
- Novartis
- Partner Therapeutics
- Teva Pharmaceuticals Industries
PART 15: APPENDIX